Sodium-glucose co-transporter 2: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Badgettrg (talk | contribs)
Bureaucrats, exportpages, nocaptcha, nukepages, oversight, Administrators, Widget editors
3,792 edits
No edit summary
Badgettrg (talk | contribs)
Bureaucrats, exportpages, nocaptcha, nukepages, oversight, Administrators, Widget editors
3,792 edits
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Sodium-dependent glucose cotrasporter 2''' are a family of [[glucose transporter]] expressed in the luminal membrane of the [[proximal kidney tubule]]s. They contribute to [[renal glucose reabsorption]].{{MeSH|Sodium-Glucose Transporter 2}}
{{protein
| Name = solute carrier family 5 (sodium/glucose cotransporter), member 2
| caption =
| image =
| width =
| HGNCid = 11037
| Symbol = SLC5A2
| AltSymbols = SGLT2
| EntrezGene = 6524
| OMIM = 182381
| RefSeq = NM_003041
| UniProt = P31639
| PDB =
| ECnumber =
| Chromosome = 16
| Arm = p
| Band = 11.2
| LocusSupplementaryData =
}}
 
{{SI}}
 
==Overview==
'''Sodium-dependent glucose cotrasporter 2''' are a family of [[glucose transporter]] "expressed in the luminal membrane of the [[proximal kidney tubule]]s"<ref> Anonymous 2015, [http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?term={{PAGENAME}} {{PAGENAME}}]. Medical Subject Headings. U.S. National Library of Medicine.</ref>. They contribute to [[renal glucose reabsorption]].
 
==Pharmacology==
===Inhibitors===
* Canagliflozin
* Dapagliflozin
* Empagliflozin
* Gliflozin
 
Inhibitors improve glycemic control<ref name="pmid24026259">{{cite journal| author=Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E et al.| title=Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. | journal=Ann Intern Med | year= 2013 | volume= 159 | issue= 4 | pages= 262-74 | pmid=24026259 | doi=10.7326/0003-4819-159-4-201308200-00007 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24026259  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24445708 Review in: Ann Intern Med. 2014 Jan 21;160(2):JC10] </ref> and may reduce clinical outcomes<ref name="pmid26378978">{{cite journal| author=Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al.| title=Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. | journal=N Engl J Med | year= 2015 | volume=  | issue=  | pages=  | pmid=26378978 | doi=10.1056/NEJMoa1504720 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26378978  }} </ref>.
 
==References==
<references/>
 
==External links==
* {{MeshName|Sodium-Glucose+Transporter+2}}
 
{{Ion pumps}}
{{Membrane transport proteins}}

Latest revision as of 04:10, 29 September 2015

solute carrier family 5 (sodium/glucose cotransporter), member 2
Identifiers
SymbolSLC5A2
Alt. symbolsSGLT2
Entrez6524
HUGO11037
OMIM182381
RefSeqNM_003041
UniProtP31639
Other data
LocusChr. 16 p11.2

WikiDoc Resources for Sodium-glucose co-transporter 2

Articles

Most recent articles on Sodium-glucose co-transporter 2

Most cited articles on Sodium-glucose co-transporter 2

Review articles on Sodium-glucose co-transporter 2

Articles on Sodium-glucose co-transporter 2 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sodium-glucose co-transporter 2

Images of Sodium-glucose co-transporter 2

Photos of Sodium-glucose co-transporter 2

Podcasts & MP3s on Sodium-glucose co-transporter 2

Videos on Sodium-glucose co-transporter 2

Evidence Based Medicine

Cochrane Collaboration on Sodium-glucose co-transporter 2

Bandolier on Sodium-glucose co-transporter 2

TRIP on Sodium-glucose co-transporter 2

Clinical Trials

Ongoing Trials on Sodium-glucose co-transporter 2 at Clinical Trials.gov

Trial results on Sodium-glucose co-transporter 2

Clinical Trials on Sodium-glucose co-transporter 2 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sodium-glucose co-transporter 2

NICE Guidance on Sodium-glucose co-transporter 2

NHS PRODIGY Guidance

FDA on Sodium-glucose co-transporter 2

CDC on Sodium-glucose co-transporter 2

Books

Books on Sodium-glucose co-transporter 2

News

Sodium-glucose co-transporter 2 in the news

Be alerted to news on Sodium-glucose co-transporter 2

News trends on Sodium-glucose co-transporter 2

Commentary

Blogs on Sodium-glucose co-transporter 2

Definitions

Definitions of Sodium-glucose co-transporter 2

Patient Resources / Community

Patient resources on Sodium-glucose co-transporter 2

Discussion groups on Sodium-glucose co-transporter 2

Patient Handouts on Sodium-glucose co-transporter 2

Directions to Hospitals Treating Sodium-glucose co-transporter 2

Risk calculators and risk factors for Sodium-glucose co-transporter 2

Healthcare Provider Resources

Symptoms of Sodium-glucose co-transporter 2

Causes & Risk Factors for Sodium-glucose co-transporter 2

Diagnostic studies for Sodium-glucose co-transporter 2

Treatment of Sodium-glucose co-transporter 2

Continuing Medical Education (CME)

CME Programs on Sodium-glucose co-transporter 2

International

Sodium-glucose co-transporter 2 en Espanol

Sodium-glucose co-transporter 2 en Francais

Business

Sodium-glucose co-transporter 2 in the Marketplace

Patents on Sodium-glucose co-transporter 2

Experimental / Informatics

List of terms related to Sodium-glucose co-transporter 2

Overview

Sodium-dependent glucose cotrasporter 2 are a family of glucose transporter "expressed in the luminal membrane of the proximal kidney tubules"[1]. They contribute to renal glucose reabsorption.

Pharmacology

Inhibitors

  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • Gliflozin

Inhibitors improve glycemic control[2] and may reduce clinical outcomes[3].

References

  1. ↑ Anonymous 2015, co-transporter 2 Sodium-glucose co-transporter 2. Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E; et al. (2013). "Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis". Ann Intern Med. 159 (4): 262–74. doi:10.7326/0003-4819-159-4-201308200-00007. PMID 24026259. Review in: Ann Intern Med. 2014 Jan 21;160(2):JC10
  3. ↑ Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S; et al. (2015). "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes". N Engl J Med. doi:10.1056/NEJMoa1504720. PMID 26378978.

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Sodium-glucose_co-transporter_2&oldid=1164806"